{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:12:54Z","timestamp":1789225974026,"version":"build-2803163510"},"reference-count":26,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"published-print":{"date-parts":[[1996,8,1]]},"DOI":"10.1136\/gut.39.2.279","type":"journal-article","created":{"date-parts":[[2007,9,18]],"date-time":"2007-09-18T21:41:31Z","timestamp":1190151691000},"page":"279-283","source":"Crossref","is-referenced-by-count":158,"title":["Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients."],"prefix":"10.1136","volume":"39","author":[{"given":"P","family":"Ruszniewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Chayvialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Blumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Dupas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gouerou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Genestin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bernades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Rougier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon","volume":"2","author":"Janson, E.T.; Oberg, K.","year":"1993","unstructured":"Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 2: 225-9.","journal-title":"Acta Oncol"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4","article-title":"Carcinoid tumors. An analysis of 2837 cases","volume":"2","author":"Godwin, J.D.","year":"1975","unstructured":"Godwin JD. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 2: 560-9.","journal-title":"Cancer"},{"key":"ref_3","first-page":"1503","article-title":"An odessey in the land of small tumors","volume":"10","author":"Moertel, C.G.","year":"1987","unstructured":"Moertel CG. An odessey in the land of small tumors. Jf Clin Oncol 1987; 10: 1503-23.","journal-title":"Jf Clin Oncol"},{"key":"ref_4","first-page":"1560","article-title":"The carcinoid syndrome","volume-title":"disease. Pathophysiology, diagnosis, management","author":"Kowlessar, O.D.","year":"1989","unstructured":"Kowlessar OD. The carcinoid syndrome. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease. Pathophysiology, diagnosis, management. 4th ed. Philadelphia: W B Saunders, 1989: 1560-70.","edition":"4th ed"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0889-8529(18)30382-7","article-title":"Therapy of the malignant carcinoid syndrome","volume":"2","author":"Kvols, L.K.","year":"1989","unstructured":"Kvols LK. Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin North Am 1989; 2: 557-68.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/0003-4819-73-4-607","article-title":"Serotinin now; clinical implications of inhibiting its synthesis with parachlorophenylalanine","volume":"73","author":"Sjoerdsma, A.; Lovenberg, W.; Engelman, K.","year":"1970","unstructured":"Sjoerdsma A, Lovenberg W, Engelman K. Serotinin now; clinical implications of inhibiting its synthesis with parachlorophenylalanine. Ann Intern Med 1970; 73: 607-29.","journal-title":"Ann Intern Med"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/1097-0142(19910101)67:1<33::AID-CNCR2820670107>3.0.CO;2-E","article-title":"A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"67","author":"Moertel, C.G.; Kvols, L.K.; Rubin, J.","year":"1991","unstructured":"Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991; 67: 33-6.","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM197811092991908","article-title":"The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin","volume":"299","author":"Frolich, J.C.; Bloomgarden, Z.T.; Oates, J.A.; McGuigan, J.E.; Rabinowitz, D.","year":"1978","unstructured":"Frolich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitz D. The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl Jf Med 1978; 299: 1055-7.","journal-title":"N Engl Jf Med"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.22.7.549","article-title":"gastrointestinal peptides and the carcinoid syndrome","volume":"22","author":"true","year":"1981","unstructured":"Long RG, Peters JR, Bloom SR, Brown MR, Vale W, Rivier JE, et al. Somatostatin, gastrointestinal peptides and the carcinoid syndrome. Gut 1981; 22: 549-53.","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.","year":"1973","unstructured":"Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/0003-4819-110-1-35","article-title":"Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut","volume":"110","author":"Gorden, P.; Comi, R.J.; Maton, P.N.; Go, V.L.W.","year":"1989","unstructured":"Gorden P, Comi RJ, Maton PN, Go VLW. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35-50.","journal-title":"Ann Intern Med"},{"key":"ref_12","first-page":"663","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"11","author":"Kvols, L.K.; Moertel, C.G.; O'Connell, M.J.; Schutt, A.J.; Rubin, J.; Hahn, R.G.","year":"1986","unstructured":"Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. NEnglJfMed 1986; 11: 663-6.","journal-title":"NEnglJfMed"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/BF01655110","article-title":"Use of octreotide acetate for control of symptoms in patients with islet cell tumors","volume":"17","author":"Maton, P.N.","year":"1993","unstructured":"Maton PN. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World Jf Surg 1993; 17: 504-10.","journal-title":"World Jf Surg"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/1097-0142(19870501)59:9<1654::AID-CNCR2820590922>3.0.CO;2-C","article-title":"Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome","volume":"59","author":"Souquet, J.C.; Sassolas, G.; Forichon, J.; Champetier, P.; Partensky, C.; Chayvialle, J.A.","year":"1987","unstructured":"Souquet JC, Sassolas G, Forichon J, Champetier P, Partensky C, Chayvialle JA. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987; 59: 1654-60.","journal-title":"Cancer"},{"key":"ref_15","first-page":"24","article-title":"The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors","volume":"27","author":"Trautmann, M.E.; Neuhaus, C.; Lenze, H.; Benning, R.; Benning, M.; Dennler, H.J.","year":"1995","unstructured":"Trautmann ME, Neuhaus C, Lenze H, Benning R, Benning M, Dennler HJ, et al. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Horm Metab Res 1995; 27: 24-7.","journal-title":"Horm Metab Res"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/jcem-68-2-239","article-title":"Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin and digestive peptides in normal men","volume":"68","author":"Sassolas, G.; Khalfallah, Y.; Chayvialle, J.A.","year":"1989","unstructured":"Sassolas G, Khalfallah Y, Chayvialle JA. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin and digestive peptides in normal men. J. Clin Endocrinol Metab 1989; 68: 239-46.","journal-title":"J. Clin Endocrinol Metab"},{"key":"ref_17","first-page":"145","article-title":"Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide","volume":"79","author":"Morange, I.; De Boisvilliers, F.; Chanson, P.; Lucas, B.; Dewailly, D.; Catus, F.","year":"1994","unstructured":"Morange I, De Boisvilliers F, Chanson P, Lucas B, Dewailly D, Catus F, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79: 145-51.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF01536042","article-title":"Use of somatostatin analog in management of carcinoid syndrome","volume":"34","author":"Vinik, A.; Moattari, A.R.","year":"1989","unstructured":"Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34 (suppl): 14-27S.","journal-title":"Dig Dis Sci"},{"key":"ref_19","first-page":"185","article-title":"Long term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible","volume-title":"shrinkage of metastases. Gastroenterology 1985; 88","author":"Kraenzlin, M.E.; Ch'ng, J.L.C.; Wood, S.M.; Carr, K.H.; Bloom, SR","unstructured":"Kraenzlin ME, Ch'ng JLC, Wood SM, Carr KH, Bloom SR. Long term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185-7."},{"key":"ref_20","first-page":"1591","article-title":"Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide","volume":"10","author":"Scherubl, H.; Wiedenmann, B.; Riecken, E.O.; Thomas, F.; B6hme, E.; RUth, U.","year":"1994","unstructured":"Scherubl H, Wiedenmann B, Riecken EO, Thomas F, B6hme E, RUth U. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. EurJ Cancer 1994; 10: 1591-2.","journal-title":"EurJ Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz, L.; Trochanowski, B.; Buckley, M.; Heffernan, B.; Niedzwiecki, D.","year":"1993","unstructured":"Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244-8.","journal-title":"Cancer"},{"key":"ref_22","first-page":"385","article-title":"Somatostatin analogues in the management of endocrine tumors of the pancreas","volume-title":"Endocrine tumors of the pancreas. Front Gastrointest Res","volume":"23","author":"Scarpignato, C.","year":"1995","unstructured":"Scarpignato C. Somatostatin analogues in the management of endocrine tumors of the pancreas. In: Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas. Front Gastrointest Res. Basel: Karger, 1995; 23: 385-414."},{"issue":"1","key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000200257","article-title":"Sandostatin and carcinoid tumours in France: experience in the Lyon area","volume":"45","author":"Chayvialle, J.A.","year":"1990","unstructured":"Chayvialle JA. Sandostatin and carcinoid tumours in France: experience in the Lyon area. Digestion 1990; 45 (suppl 1): 23-6.","journal-title":"Digestion"},{"key":"ref_24","first-page":"107","article-title":"Gallstones during octreotide therapy","volume":"1","author":"Dowling, R.H.; Hussaini, S.H.; Murphy, G.M.; Wass, J.A.H.","year":"1993","unstructured":"Dowling RH, Hussaini SH, Murphy GM, Wass JAH. Gallstones during octreotide therapy. Digestion 1993; 54 (suppl 1): 107-20.","journal-title":"Digestion"},{"key":"ref_25","first-page":"319","article-title":"Long-term treatment of the carcinoid syndrome by lanreotide: results of a prospective multicentre study","volume":"106","author":"Ruszniewski, P.; Ducreux, M.; Michel, H.; Amouretti, M.; Gouerou, H.; Wemeau, J.L.","year":"1994","unstructured":"Ruszniewski P, Ducreux M, Michel H, Amouretti M, Gouerou H, Wemeau JL, et al. Long-term treatment of the carcinoid syndrome by lanreotide: results of a prospective multicentre study. Gastroenterology 1994; 106 (suppl): A319.","journal-title":"Gastroenterology"},{"key":"ref_26","first-page":"246","volume":"334","author":"Lamberts, S.W.J.; Van Der Ley, A.J.; De Herder, W.W.; Hofland, U.","year":"1996","unstructured":"Lamberts SWJ, Van Der Ley AJ, De Herder WW, Hofland U. Octreotide. NEngl_JMed 1996; 334: 246-54.","journal-title":"Octreotide. NEngl_JMed"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gut.39.2.279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T03:28:12Z","timestamp":1601090892000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gut.39.2.279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,8,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1996,8,1]]}},"URL":"https:\/\/doi.org\/10.1136\/gut.39.2.279","relation":{},"ISSN":["0017-5749"],"issn-type":[{"value":"0017-5749","type":"print"}],"subject":[],"published":{"date-parts":[[1996,8,1]]}}}